Plotnikov Alexei N, Sosunov Eugene A, Qu Jihong, Shlapakova Iryna N, Anyukhovsky Evgeny P, Liu Lili, Janse Michiel J, Brink Peter R, Cohen Ira S, Robinson Richard B, Danilo Peter, Rosen Michael R
Center for Molecular Therapeutics, Department of Pharmacology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Circulation. 2004 Feb 3;109(4):506-12. doi: 10.1161/01.CIR.0000114527.10764.CC. Epub 2004 Jan 20.
We hypothesized that administration of the HCN2 gene to the left bundle-branch (LBB) system of intact dogs would provide pacemaker function in the physiological range of heart rates.
An adenoviral construct incorporating HCN2 and green fluorescent protein (GFP) as a marker was injected via catheter under fluoroscopic control into the posterior division of the LBB. Controls were injected with an adenoviral construct of GFP alone or saline. Animals were monitored electrocardiographically for up to 7 days after surgery, at which time they were anesthetized and subjected to vagal stimulation to permit emergence of escape pacemakers. Hearts were then removed and injection sites visually identified and removed for microelectrode study of action potentials, patch clamp studies of pacemaker current, and/or immunohistochemical studies of HCN2. For 48 hours postoperatively, 7 of 7 animals subjected to 24-hour ECG monitoring showed multiple ventricular premature depolarizations and/or ventricular tachycardia attributable to injection-induced injury. Thereafter, sinus rhythm prevailed. During vagal stimulation, HCN2-injected dogs showed rhythms originating from the left ventricle, the rate of which was significantly more rapid than in the controls. Excised posterior divisions of the LBB from HCN2-injected animals manifested automatic rates significantly greater than the controls. Isolated tissues showed immunohistochemical and biophysical evidence of overexpressed HCN2.
A gene-therapy approach for induction of biological pacemaker activity within the LBB system provides ventricular escape rhythms that have physiologically acceptable rates. Long-term stability and feasibility of the approach remain to be tested.
我们假设,将HCN2基因导入完整犬的左束支(LBB)系统可在心率的生理范围内提供起搏功能。
在荧光镜控制下,通过导管将一种包含HCN2和作为标记物的绿色荧光蛋白(GFP)的腺病毒构建体注入LBB后分支。对照组分别注射单独的GFP腺病毒构建体或生理盐水。术后对动物进行长达7天的心电图监测,之后将其麻醉并进行迷走神经刺激以促使逸搏起搏器出现。然后取出心脏,目视识别并切除注射部位,用于动作电位的微电极研究、起搏电流的膜片钳研究和/或HCN2的免疫组织化学研究。术后48小时内,接受24小时心电图监测的7只动物中有7只出现了归因于注射诱导损伤的多次室性早搏和/或室性心动过速。此后,窦性心律占主导。在迷走神经刺激期间,注射HCN2的犬出现源自左心室的节律,其速率明显快于对照组。从注射HCN2的动物中切除的LBB后分支表现出明显高于对照组的自律速率。分离的组织显示出HCN2过表达的免疫组织化学和生物物理学证据。
一种在LBB系统内诱导生物起搏活动的基因治疗方法可提供具有生理可接受速率的心室逸搏节律。该方法的长期稳定性和可行性仍有待测试。